Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Multivalent vaccine for filariasis

A polyvalent vaccine, filamentous technology, applied in the field of Am.J.T in 2007, can solve problems such as difficulties

Active Publication Date: 2013-09-11
THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
View PDF1 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it may be difficult to combat this infectious disease with a single-antigen vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multivalent vaccine for filariasis
  • Multivalent vaccine for filariasis
  • Multivalent vaccine for filariasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Embodiment 1: small heat shock protein vaccine

[0053] parasites. B. malayi L3 was obtained from the NIAID / NIH Filariasis Research Reagent Resource Center (FR3) at the University of Georgia, Athens, GA.

[0054] Human serum samples. About 10 ml of blood samples were collected from the following groups of clinical subjects: (1) normal (EN) subjects in endemic areas, who were asymptomatic and without microfilariasis; (2) asymptomatic subjects with microfilariasis (Mt ), who had circulating microfilariae in the blood, and were identified by microscopic examination of their overnight blood smears; (3) patients with chronic disease (CP), including other chronic diseases exhibiting lymphoedema and filariasis subjects with clinical symptoms; and (4) normal subjects (NEN) in non-endemic areas who live in non-endemic areas and do not have circulating parasites or antibodies and do not show any signs of filariasis. Serum was separated from their blood samples and stored at -8...

Embodiment 2

[0106] Embodiment 2: rBmALT-2+rBmHSP multivalent vaccine

[0107] parasites. Brugia malayi L3 was obtained from the NIAID / NIH Filariasis Research Reagent Resource Center (FR3) at the University of Georgia, Athens, GA.

[0108]Construction of monovalent and multivalent DNA vaccines. The monovalent DNA vaccine consisted of Bmhsp or Bmalt-2 in the pVAX1 vector. To prepare a monovalent vaccine, the codon-optimized Bmhsp or Bmalt-2 gene was cloned into the eukaryotic expression vector pVAX1 (Invitrogen, Carlsbad, CA) using insert-specific primers (Gnanasekar et al., (2004) supra). The multivalent vaccine consists of the Bmhsp and Bmalt-2 genes in the same pVAX1 vector. The codon-optimized Bmhsp gene was first cloned in the pVAX1 vector without a stop codon (5'-CCG GAA TTC TCA CTT GTC GTT GGT G-3'; SEQ ID NO: 24) but containing PstI in the reverse primer location. The codon-optimized Bmalt-2 gene was then inserted into this clone using gene-specific primers (Gnanasekar et al., ...

Embodiment 3

[0123] Embodiment 3: BmVal-1+BmALT-2 multivalent vaccine

[0124] serum. The serum samples used in this study were obtained from the archived samples stored at the Mahatma Gandhi Institute of Medical Sciences, Sevagram, India. These samples were collected as part of an epidemiological investigation in and around Wardha, an area endemic for lymphatic filariasis.

[0125] Demographic data were not available from this study, except for serum samples classified as microfilariasis (MF), chronic disease, or by assessment of clinical signs of lymphatic filariasis based on circulating parasites, detection of parasite antigens (CP) or normal (EN) samples from endemic areas. Circulating microfilariae in blood of subjects were detected according to known methods (Haslbeck et al. (2005) Nat. Struct. Mol. Biol. 12:842-846; Yoo et al. (2005) Biotechnol. Lett. 27:443-448) . The Og4C3 kit and WbSXP-based enzyme-linked immunosorbent assay (ELISA) were used to detect the presence of circula...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention is a multivalent vaccine for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent vaccine are protein-based, DNA-based, or a combination thereof.

Description

[0001] Introduction [0002] This patent application claims U.S. Provisional Application Serial No. 61 / 413,681 filed November 15, 2010, U.S. Provisional Application Serial No. 61 / 449,954 filed March 7, 2011, and U.S. Provisional Application Serial No. 61 / 449,954 filed August 10, 2011 Priority benefit of Ser. No. 61 / 522,079, the contents of each of the above provisional applications are hereby incorporated by reference in their entirety. [0003] This invention was made with Government support under Contract No. 5R01AI064745-04 awarded by the National Institutes of Health. The US Government has certain rights in this invention. Background technique [0004] Lymphatic filariasis, caused by the filamentous nematodes Wuchereria Bancrofti, Brugia malayi and Brugia timori, infects more than 120 million people worldwide People (WHO (1992) World Health Organ. Tech. Rep. Ser. 821:1-71). The World Health Organization's Mass drug administration program has significantly reduced the in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/002A61K48/00A61K38/17A61P31/12
CPCA61K39/0003A61K2039/53A61P31/12Y02A50/30C07K14/4354
Inventor 拉马斯瓦米·卡尔亚纳桑达拉姆
Owner THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com